BerGenBio ASA (OTCPK:BRRGF)
$ 2.5 0 (0%) Market Cap: 27.51 Mil Enterprise Value: 17.20 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 59/100

Q1 2022 Bergenbio ASA Earnings Call Transcript

May 24, 2022 / 08:00AM GMT
Release Date Price: $177
Operator

Ladies and gentlemen, welcome to the BerGenBio Q1 2022 Conference Call. (Operator Instructions) This conference is being recorded.

I will now hand it over to the speakers. Please begin.

Martin Olin
BerGenBio ASA - CEO

Thank you very much for the introduction. Good morning. I'm Martin Olin, the CEO of BerGenBio. I'm very pleased to present to you with our Q1 highlights and financials for the first quarter. I'll just remind everyone about the forward-looking statements.

So this is a snapshot of BerGenBio. BerGenBio is a world leader in exploring (inaudible) transformative treatment modality for severe diseases. The development focus going forward will be focused on bemcentinib, our lead program, which has been dosed in more than 600 patients as of today, approximately 400 in oncology and 200 in COVID. And we are moving bemcentinib forward in 2 significant indications: One, a biomarker-driven population in first-line non-small cell lung cancer, which is carrying or harboring a mutation in the STK11 gene.

The second opportunity we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot